Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00227305 · ClinicalTrials.gov registry record · Phase 3
Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 381
- Enrollment target
NCT00227305 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 381 participants.
The verdict
NCT00227305, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 381 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate (SEROQUEL) in the treatment of adolescent patients with schizophrenia and bipolar I disorder.
Interventions
- DRUG quetiapine fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00227305
The ClinicalTrials.gov registry entry for NCT00227305 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 381 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which quetiapine fumarate is the first listed.
NCT00227305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00227305 about?
NCT00227305 is a clinical study titled "Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder". The purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate (SEROQUEL) in the treatment of adolescent patients with schizophrenia and bipolar I disorder.
What is the current status of trial NCT00227305?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 381 participants. The study started on 2004-08. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00227305?
The interventions under investigation include: quetiapine fumarate (DRUG).
Who is sponsoring clinical trial NCT00227305?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.